Filtered By:
Drug: Cilostazol

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 208 results found since Jan 2013.

Drug-drug interactions associated with antiplatelet therapy.
Authors: Dunn SP, Macaulay TE Abstract Antiplatelet therapy is of paramount importance in the treatment and prevention of adverse cardiovascular events and stroke. Drug-drug interactions (DDIs) among antiplatelet therapies have been growing in both prevalence and clinical importance. Most DDIs with antiplatelet therapies are pharmacodynamic in nature. DDIs with thienopyridines and proton pump inhibitors have resulted in advisories from regulatory agencies although the full significance of this interaction is unknown. Other DDIs with thienopyridines may potentially exist with statins, calcium channel blockers, and w...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - November 23, 2014 Category: Cardiology Tags: Cardiovasc Hematol Agents Med Chem Source Type: research

The effect of cilostazol and aspirin pre-treatment against subsequent transient focal cerebral ischemia in rat.
We examined whether 7 days of oral administration of cilostazol protects against subsequent cerebral ischemia, and whether or not the effect of combination therapy with aspirin is more protective. METHODS: We used Sprague-Dawley (SD) rats and assigned them to four groups: vehicle, aspirin, cilostazol, and aspirin plus cilostazol combination therapy. After oral administration of anti-platelets for 7 days, we performed transient middle cerebral artery occlusion (MCAO) for 90 minutes, and examined infarct volume, neurological symptoms, and regional cerebral blood flow (rCBF). Immunostaining of Bax, Bcl-2, TUNEL, 4-HNE, 8-...
Source: Neurological Research - December 2, 2014 Category: Neurology Tags: Neurol Res Source Type: research

Hemichorea in a diabetes mellitus patient following acute ischemic stroke with changes in regional cerebral blood flow
Publication date: Available online 4 March 2015 Source:Journal of the Chinese Medical Association Author(s): Yutaka Suzuki , Minoru Oishi , Akira Kanno , Katsuhiko Ogawa , Mariko Fujisawa , Satoshi Kamei It is not unusual to observe hemichorea in patients with diabetes mellitus, with origins attributable to recent ischemia. Our patient was a 66-year-old female with diabetes mellitus who suddenly developed right hemichorea, mild muscle weakness of the right upper extremity, ideational apraxia, and acalculia. Her blood glucose was 600 mg/dL, and HbA1c was 13.3%. After the patient underwent head magnetic resonance imaging ...
Source: Journal of the Chinese Medical Association - March 4, 2015 Category: Journals (General) Source Type: research

Optimal- vs. standard-antiplatelet therapy on platelet function and long-term clinical outcomes in patients with high on-treatment platelet reactivity: 2-year outcomes of the multicentre, randomized Optimal-antiPlatelet Therapy (OPT) trial
Optimal strategy for the management of high on-treatment platelet reactivity (HPR), an independent predictor of ischaemic events, is not yet clear. The aim of this study was to explore the safety and efficacy of personalized antiplatelet therapy based on platelet function testing in patients with HPR. A total of 840 patients with HPR who underwent coronary stenting for acute coronary syndrome (ACS) were randomly assigned in a 1:2 ratio to receive standard dual-antiplatelet therapy (n = 280) or platelet function-guided optimal-antiplatelet therapy (n = 560). In the optimal group, patients initially received clopidogrel 150 ...
Source: European Journal of Heart Failure Supplements - March 23, 2015 Category: Cardiology Authors: Li, Y., Han, Y., Guan, S., Sun, Y., Guo, L., Yang, B., Zang, H., Jing, Q., Wang, X., Ma, Y., Liu, X., Li, J., Zheng, L. Tags: Articles Source Type: research

Retraction Note: Systematic study of cilostazol on secondary stroke prevention: a meta-analysis
Source: European Journal of Medical Research - March 26, 2015 Category: Research Source Type: research

It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent
Abstract: It has been shown that triple antiplatelet therapy with cilostazol results in better clinical outcomes than dual therapy in patients treated with a first-generation drug-eluting stent (DES); however, it is unclear whether triple antiplatelet therapy has a similar efficacy after the implantation of second-generation DES. In the COACT (Cath Olic medical center percutAneous Coronary in Tervention) registry, 1248 study subjects who underwent percutaneous coronary intervention with an everolimus- or zotarolimus-eluting stent (Endeavor, Xience V, or Promus) were analyzed. The patients were divided into 2 groups after p...
Source: Medicine - November 1, 2015 Category: Internal Medicine Tags: Observational Study Source Type: research

Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial
Conclusions In patients who underwent coronary stent implantation, the addition of cilostazol to aspirin therapy was associated with lower rates of cardiovascular and cerebrovascular events at 2 years compared with aspirin monotherapy.
Source: American Heart Journal - January 12, 2016 Category: Cardiology Source Type: research

Continuous daily use of cilostazol prevents in-stent restenosis following carotid artery stenting: serial angiographic investigation of 229 lesions
Conclusions An overall cumulative ISR rate of 5.6% was documented angiographically at 1 year after CAS. Continuous daily use of CLS (for at least 1 year) may have a beneficial effect on long term prevention of ISR.
Source: Journal of NeuroInterventional Surgery - April 13, 2016 Category: Neurosurgery Authors: Miyazaki, Y., Mori, T., Iwata, T., Aoyagi, Y., Tanno, Y., Kasakura, S., Yoshioka, K. Tags: Ischemic stroke Source Type: research

Modulatory effect of cilostazol on tramadol-induced behavioral and neurochemical alterations in rats challenged across the forced swim despair test
Publication date: Available online 30 May 2016 Source:Beni-Suef University Journal of Basic and Applied Sciences Author(s): Noha M. Gamil, Yousreya A. Maklad, Maha A.E. Ahmed, Shahira Nofal, Amany A.E. Ahmed Pain-associated depression is encountered clinically in some cases such as cancer, chronic neuropathy, and after operations. Tramadol is an opioid analgesic drug that may modulate monoaminergic neurotransmission by inhibition of noradrenaline and serotonin reuptake that may contribute to its antidepressant-like effects. Clinically, tramadol is used either alone or in combination with other NSAIDs in the treatmen...
Source: Beni Suef University Journal of Basic and Applied Sciences - May 30, 2016 Category: Science Source Type: research

Cilostazol protects against microvascular brain injury in a rat model of type 2 diabetes
Publication date: Available online 8 December 2016 Source:Neuroscience Research Author(s): Yuko Tsukamoto, Eiichiro Nagata, Naoto Fukuyama, Yoshiko Itoh, Kimiko Yuzawa, Saori Kohara, Mie Shimizu, Yoko Takahari, Shunya Takizawa Cilostazol, a pluripotent phosphodiesterase III-specific inhibitor with anti-platelet and vasculogenic effects, is useful for preventing recurrent brain vascular events, particularly in stroke patients with diabetes mellitus (DM). However, it is unclear whether cilostazol affects autoregulatory responses in small cerebral arteries. Thus, we investigated the effect of cilostazol on diabetic brain vas...
Source: Neuroscience Research - December 8, 2016 Category: Neuroscience Source Type: research

Cilostazol Fails to Best Aspirin for Post-Stroke Secondary Prevention (CME/CE)
(MedPage Today) -- Non-inferior overall but MI rates higher with PDE3 inhibitor
Source: MedPage Today Geriatrics - February 25, 2017 Category: Geriatrics Source Type: news

Antiplatelet Therapy Combinations and Thrombogenicity in Patients with Non-Valvular Atrial Fibrillation.
CONCLUSION: In patients with NVAF, combination antiplatelet therapy showed reductions for vWF:Ag and fibrinogen levels, which may be associated with the inhibitory levels of ADP-mediated PR. The clinical implications of these findings need to be evaluated in future trials. PMID: 28567087 [PubMed - in process]
Source: Korean Circulation Journal - June 3, 2017 Category: Cardiology Tags: Korean Circ J Source Type: research

Effects of cilostazol and renin-angiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study
Conclusion Treatment with cilostazol plus ACEI or ARB was observed to prevent worsening of renal progression in patients in the stages 1 –2.
Source: International Journal of Clinical Pharmacy - December 27, 2017 Category: Drugs & Pharmacology Source Type: research

Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation?
CONCLUSION: More potent antithrombotic regimens increase bleeding and should only be considered on an individual basis, after careful risk stratification. Accurate risk stratification of ACS patients, for both ischaemic and bleeding risk, is essential to allow individualised treatment. PMID: 29345587 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - January 16, 2018 Category: Drugs & Pharmacology Authors: Spinthakis N, Farag M, Akhtar Z, Gorog DA Tags: Curr Vasc Pharmacol Source Type: research

Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol versus Standard Dual Anti-platelet in Patients with High Post-Treatment Platelet Reactivity: Results of the CREATIVE Trial (Clopidogrel Response Evaluation and AnTi-platelet InterVEntion in High Thrombotic Risk PCI Patients).
Conclusions -In patients with low responsiveness to clopidogrel, as measured by thromboelastography, the intensified antiplatelet strategies with adjunctive use of cilostazol significantly improved the clinical outcomes without increasing the risk of major bleeding. Decreased trend of negative outcomes could be observed in patients with double dosage of clopidogrel, but the difference was not significant. Clinical Trial Registration -URL: http://www.clinicaltrials.gov Unique Identifier: NCT01779401. PMID: 29420189 [PubMed - as supplied by publisher]
Source: Circulation - February 2, 2018 Category: Cardiology Authors: Tang YD, Wang W, Yang M, Zhang K, Chen J, Qiao S, Yan H, Wu Y, Huang X, Xu B, Gao R, Yang Y, CREATIVE investigators Tags: Circulation Source Type: research